dc.creator | Koliarakis I., Athanasakis E., Sgantzos M., Mariolis-Sapsakos T., Xynos E., Chrysos E., Souglakos J., Tsiaoussis J. | en |
dc.date.accessioned | 2023-01-31T08:43:35Z | |
dc.date.available | 2023-01-31T08:43:35Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.3390/cancers12103011 | |
dc.identifier.issn | 20726694 | |
dc.identifier.uri | http://hdl.handle.net/11615/74969 | |
dc.description.abstract | The intestinal microbiota consists of numerous microbial species that collectively interact with the host, playing a crucial role in health and disease. Colorectal cancer is well-known to be related to dysbiotic alterations in intestinal microbiota. It is evident that the microbiota is significantly affected by colorectal surgery in combination with the various perioperative interventions, mainly mechanical bowel preparation and antibiotic prophylaxis. The altered postoperative composition of intestinal microbiota could lead to an enhanced virulence, proliferation of pathogens, and diminishment of beneficial microorganisms resulting in severe complications including anastomotic leakage and surgical site infections. Moreover, the intestinal microbiota could be utilized as a possible biomarker in predicting long-term outcomes after surgical CRC treatment. Understanding the underlying mechanisms of these interactions will further support the establishment of genomic mapping of intestinal microbiota in the management of patients undergoing CRC surgery. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. | en |
dc.language.iso | en | en |
dc.source | Cancers | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092574082&doi=10.3390%2fcancers12103011&partnerID=40&md5=6b4505113168fcd45250466b0238c4ab | |
dc.subject | amoxicillin plus clavulanic acid | en |
dc.subject | ampicillin | en |
dc.subject | antibiotic agent | en |
dc.subject | cefazolin | en |
dc.subject | ciprofloxacin | en |
dc.subject | clindamycin | en |
dc.subject | levofloxacin | en |
dc.subject | metronidazole | en |
dc.subject | piperacillin plus tazobactam | en |
dc.subject | quinolone derivative | en |
dc.subject | sulbactam | en |
dc.subject | anastomosis leakage | en |
dc.subject | antibiotic therapy | en |
dc.subject | cancer patient | en |
dc.subject | cancer surgery | en |
dc.subject | carcinogenesis | en |
dc.subject | clinical effectiveness | en |
dc.subject | clinical outcome | en |
dc.subject | colorectal cancer | en |
dc.subject | denaturing gradient gel electrophoresis | en |
dc.subject | high throughput sequencing | en |
dc.subject | human | en |
dc.subject | intestine flora | en |
dc.subject | intestine preparation | en |
dc.subject | nonhuman | en |
dc.subject | perioperative period | en |
dc.subject | postoperative complication | en |
dc.subject | preoperative period | en |
dc.subject | Review | en |
dc.subject | surgical infection | en |
dc.subject | surgical stress | en |
dc.subject | MDPI AG | en |
dc.title | Intestinal microbiota in colorectal cancer surgery | en |
dc.type | other | en |